Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Psoriasis
Interventions
DRUG

Methotrexate

Initial dose 5 mg, then 15 mg per week

DRUG

Raptiva

Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg

Trial Locations (1)

95816

University of California, Davis Medical Center Department of Dermatology, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, Davis

OTHER